A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Castle Biosciences,” the “Company,” “we,” “us” and “our” refer to Castle Biosciences, Inc., a Delaware Corporation. Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (“BE”), atopic dermatitis (“AD”), uveal melanoma (“UM”). Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation. Our Testing Solutions Our tests are designed to deliver personalized information to help better inform clinical care decisions.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 344M | 344M | 332M | 220M | 137M | 94M |
| Net Income | -24M | -24M | 18M | -57M | -67M | -31M |
| EPS | $-0.83 | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 |
| Free Cash Flow | 28M | 28M | 37M | -19M | -47M | -22M |
| ROIC | -8.6% | -5.1% | - | -14.7% | -16.8% | -7.6% |
| Gross Margin | 79.4% | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% |
| Debt/Equity | 0.08 | 0.08 | 0.06 | 0.04 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -43M | -43M | - | -68M | -73M | -40M |
| Operating Margin | -12.4% | -12.4% | - | -30.9% | -53.2% | -42.6% |
| ROE | -5.1% | -5.2% | 4.0% | -14.7% | -16.8% | -7.6% |
| Shares Outstanding | 29M | 29M | 29M | 27M | 26M | 25M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 23M | 52M | 63M | 94M | 137M | 220M | 332M | 344M | 344M |
| Gross Margin | 76.8% | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% | 79.4% |
| R&D | 4.9M | 7.4M | 13M | 30M | 45M | 54M | 52M | 52M | 52M |
| SG&A | 16M | 30M | 48M | 87M | 143M | 180M | 200M | 229M | 229M |
| EBIT | -3.8M | 7.3M | -6.5M | -40M | -73M | -68M | N/A | -43M | -43M |
| Op. Margin | -16.8% | 14.1% | -10.4% | -42.6% | -53.2% | -30.9% | N/A | -12.4% | -12.4% |
| Net Income | -10M | 3.0M | -10M | -31M | -67M | -57M | 18M | -24M | -24M |
| Net Margin | -44.6% | 5.8% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% | -7.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -17.1% | 8.4% | -2.5% | -7.6% | -16.8% | -14.7% | N/A | -5.1% | -8.6% |
| ROE | N/A | 3.5% | -2.5% | -7.6% | -16.8% | -14.7% | 4.0% | -5.2% | -5.1% |
| ROA | -45.4% | 2.5% | -2.3% | -6.8% | -15.0% | -12.7% | 3.4% | -4.4% | -4.2% |
| Cash Flow | |||||||||
| Op. Cash Flow | -12M | 7.0M | 9.9M | -19M | -42M | -5.6M | 65M | 64M | 64M |
| Free Cash Flow | -13M | 6.1M | 5.1M | -22M | -47M | -19M | 37M | 28M | 28M |
| Owner Earnings | -13M | 5.4M | 1.1M | -44M | -89M | -69M | -1.5M | -22M | -22M |
| CapEx | 277K | 937K | 4.8M | 3.5M | 5.6M | 14M | 28M | 36M | 36M |
| Maint. CapEx | 323K | 358K | 472K | 3.4M | 11M | 12M | 16M | 41M | 41M |
| Growth CapEx | 0 | 579K | 4.3M | 76K | 0 | 1.3M | 12M | 0 | 0 |
| D&A | 323K | 358K | 472K | 3.4M | 11M | 12M | 16M | 41M | 41M |
| CapEx/OCF | N/A | 13.4% | 48.2% | N/A | N/A | N/A | 43.7% | 56.0% | 56.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 294K | 1.2M | 8.3M | 22M | 36M | 51M | 50M | 46M | 46M |
| Debt Repayment | 0 | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | 16M | -167M | -820M | -321M | -245M | -228M | -267M | -262M | -80M |
| Cash & Equiv. | 4.5M | 99M | 410M | 330M | 123M | 99M | 120M | 117M | 117M |
| Long-Term Debt | 25M | 19M | 0 | 124K | 90K | 25K | 9.7M | 9.6M | 9.6M |
| Debt/Equity | -0.43 | 0.36 | 0.00 | 0.02 | 0.03 | 0.04 | 0.06 | 0.08 | 0.08 |
| Interest Coverage | -1.7 | 1.6 | -2.5 | -40079.0 | -4285.6 | -6179.7 | N/A | -497.8 | -497.8 |
| Equity | -57M | 85M | 416M | 412M | 399M | 391M | 456M | 471M | 471M |
| Total Assets | 22M | 120M | 439M | 463M | 447M | 453M | 531M | 579M | 579M |
| Total Liabilities | 79M | 35M | 24M | 51M | 48M | 62M | 75M | 108M | 108M |
| Intangibles | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -57M | -52M | -62M | -94M | -161M | -218M | -200M | -224M | -224M |
| Working Capital | 11M | 101M | 409M | 329M | 256M | 248M | 311M | 292M | 292M |
| Current Assets | 18M | 117M | 430M | 354M | 292M | 296M | 360M | 361M | 361M |
| Current Liabilities | 6.7M | 15M | 21M | 25M | 36M | 48M | 49M | 69M | 69M |
| Per Share Data | |||||||||
| EPS | -5.33 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 | -0.83 |
| Owner EPS | -0.75 | 0.22 | 0.06 | -1.75 | -3.40 | -2.58 | -0.05 | -0.77 | -0.77 |
| Book Value | -3.29 | 3.41 | 21.83 | 16.32 | 15.34 | 14.57 | 15.49 | 16.18 | 16.18 |
| Cash Flow/Share | -0.72 | 0.28 | 0.52 | -0.75 | -1.60 | -0.21 | 2.20 | 2.21 | 0.57 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 17.2M | 25.0M | 19.0M | 25.2M | 26.0M | 26.9M | 29.4M | 29.1M | 29.1M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 43.3 | N/A | -29.4 |
| P/FCF | N/A | 139.7 | 272.0 | N/A | N/A | N/A | 21.6 | 40.5 | 25.0 |
| EV/EBIT | N/A | 93.1 | N/A | N/A | N/A | N/A | 58.4 | N/A | N/A |
| Price/Book | N/A | 10.0 | 3.3 | 2.5 | 1.4 | 1.5 | 1.7 | 2.4 | 1.5 |
| Price/Sales | N/A | 11.2 | 12.3 | 17.7 | 5.5 | 2.4 | 2.2 | 2.0 | 2.1 |
| FCF Yield | N/A | 0.7% | 0.4% | -2.2% | -8.4% | -3.2% | 4.6% | 2.5% | 4.0% |
| Market Cap | N/A | 849M | 1.4B | 1.0B | 563M | 602M | 790M | 1.1B | 709M |
| Avg. Price | N/A | 23.28 | 40.50 | 66.17 | 29.17 | 19.96 | 25.01 | 23.83 | 24.37 |
| Year-End Price | N/A | 33.99 | 73.05 | 41.20 | 21.65 | 22.43 | 26.83 | 39.40 | 24.37 |
CASTLE BIOSCIENCES INC passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 25.6x vs a median of 31.0x. The company's 5-year average gross margin is 80.1%. At current prices, the estimated annualized return to fair value is +39.4%.
CASTLE BIOSCIENCES INC (CSTL) has a 5-year average return on invested capital (ROIC) of -11.1%. This is below average and may indicate limited pricing power.
CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of $709M. It is classified as a small-cap stock.
CASTLE BIOSCIENCES INC (CSTL) does not currently pay a regular dividend.
CASTLE BIOSCIENCES INC (CSTL) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
CASTLE BIOSCIENCES INC (CSTL) reported annual revenue of $344 million in its most recent fiscal year, based on SEC EDGAR filings.
CASTLE BIOSCIENCES INC (CSTL) has a net profit margin of -7.0%. The company is currently unprofitable.
CASTLE BIOSCIENCES INC (CSTL) generated $28 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CASTLE BIOSCIENCES INC (CSTL) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
CASTLE BIOSCIENCES INC (CSTL) reported earnings per share (EPS) of $-0.83 in its most recent fiscal year.
CASTLE BIOSCIENCES INC (CSTL) has a return on equity (ROE) of -5.2%. A negative ROE may indicate losses or negative equity.
CASTLE BIOSCIENCES INC (CSTL) has a 5-year average gross margin of 80.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for CASTLE BIOSCIENCES INC (CSTL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CASTLE BIOSCIENCES INC (CSTL) has a book value per share of $16.18, based on its most recent annual SEC filing.